3rd Feb 2025 20:06
EMV Capital PLC - life sciences focused investor - Portfolio company ProAxsis plans to raise GBP800,000 via the issue of new shares. ProAxsis is a respiratory diagnostics company and a spin-out from Queens University Belfast. Proceeds will be divided as to GBP500,000 towards core business activities, and GBP300,000 towards advancing a COPD clinical study with Imperial College. In addition, ProAxsis says revenue rose 92% to GBP470,000 in 2024. EMV has a near 89% stake in ProAxsis which had a fair value of GBP8.0 million as at June 30, 2024.
Current stock price: 50.00 pence
12-month change: down 22%
By Jeremy Cutler, Alliance News reporter
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.